Our findings indicate that NPM1mut-CTLs, obtained from patients or healthy donors and endowed with leukemia-specific activity, may constitute a safe and effective option in the treatment of patients affected by refractory or relapsed NPM1-mutated AML. This evidence concerns the gene NPM1 and leukemia.